Since the 2010s, the introduction of BRAF and MEK inhibitors and immune checkpoint inhibitors targeting CTLA‐4 and PD‐1/PD‐L1 has revolutionised treatment strategies for melanoma [5]. The gene discussed is MAP2K7; the disease is melanoma.